Get the Stockscreener App
3.41
6.23%
0.20
After Hours:
3.40
-0.01
-0.29%
Turn Therapeutics Inc stock is traded at $3.41, with a volume of 67,584.
It is up +6.23% in the last 24 hours and down -22.50% over the past month.
Turn Therapeutics Inc is a clinical-stage biotechnology company focused on developing pharmaceutical and medical device products for dermatology, wound care, and infectious disease. The company's proprietary platform technology, called PermaFusion, enhances drug performance by improving the stability and bioavailability of active pharmaceutical ingredients, which allows for reduced doses and fewer side effects. Its primary development programs target skin conditions such as moderate to severe eczema and onychomycosis.
See More
Previous Close:
$3.21
Open:
$3.3
24h Volume:
67,584
Relative Volume:
0.17
Market Cap:
$100.41M
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-
EPS:
-
Net Cash Flow:
-
1W Performance:
-20.88%
1M Performance:
-22.50%
6M Performance:
+0.00%
1Y Performance:
+0.00%
1-Day Range:
$3.11
$3.555
1-Week Range:
$2.94
$4.37
52-Week Range:
$2.5701
$26.50
Turn Therapeutics Inc Stock (TTRX) Company Profile
Name
Turn Therapeutics Inc
Sector
Industry
Phone
(818) 564-4011
Address
250 NORTH WESTLAKE BLVD., WESTLAKE VILLAGE
Compare TTRX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
TTRX
Turn Therapeutics Inc
|
3.41 | 94.52M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.04 | 113.14B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
741.29 | 78.49B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
877.94 | 54.76B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
397.55 | 54.51B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
INSM
Insmed Inc
|
197.01 | 41.64B | 447.02M | -1.18B | -906.14M | -6.1812 |
Turn Therapeutics Inc Stock (TTRX) Latest News
Can Black Diamond Therapeutics (BDTX) Turn Silevertinib’s Dual-Cancer Ambition Into a Cohesive Strategy? - Yahoo Finance
Arthur Golden Increases Stake in Turn Therapeutics Inc with Rece - GuruFocus
Golden Arthur F buys Turn Therapeutics shares worth $33945 By Investing.com - Investing.com Nigeria
Golden Arthur F buys Turn Therapeutics shares worth $33945 - Investing.com
Turn Therapeutics Director Arthur F Golden Acquires 9,868 Shares - TradingView
Dir Golden Buys 9,868 ($33.9K) Of Turn Therapeutics Inc [TTRX] - TradingView
Insider Buying: Arthur Golden Acquires Additional Shares of Turn Therapeutics Inc (TTRX) - GuruFocus
Turn Therapeutics Director Arthur F. Golden Acquires 20,532 Shares - TradingView
Dir Golden Buys 20,532 ($58.9K) Of Turn Therapeutics Inc [TTRX] - TradingView
[Form 4] Turn Therapeutics Inc. Insider Trading Activity - Stock Titan
Turn Therapeutics Inc. Common Stock trading resumes - MSN
Zuraiz Chaudhary buys Turn Therapeutics (TTRX) shares worth $9,050 By Investing.com - Investing.com Nigeria
Zuraiz Chaudhary buys Turn Therapeutics (TTRX) shares worth $9,050 - Investing.com
Turn Therapeutics (TTRX) FDA Approvals, PDUFA Dates & Drug Alerts 2025 - MarketBeat
Turn Therapeutics’ GX-03 Recognized for Dermatology Innovation - MSN
Turn Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Updates - The Manila Times
Turn Therapeutics GX-03 Technology Named as One of Five Novel Mechanisms Reshaping Atopic Dermatitis Treatment by Patient Care Online Magazine - MarketScreener
Turn Therapeutics (Nasdaq: TTRX) features Dr. Robert Redfield on trust in science - Stock Titan
Turn Therapeutics’ GX-03 Technology Named as One of 'Five Novel Mechanisms Reshaping Atopic Dermatitis Treatment” by Patient Care Online Magazine - The Manila Times
Turn (NASDAQ: TTRX) named among five novel eczema mechanisms by Patient Care Online - Stock Titan
Turn Therapeutics appoints Andrew Scott as VP of Corporate Communications - Investing.com Australia
Turn Therapeutics Appoints New VP of Communications - TipRanks
Turn Therapeutics Appoints Veteran Capital Markets Executive Andrew Scott as Vice President of Corporate Communications - The Globe and Mail
Turn Therapeutics appoints Andrew Scott as VP of Corporate Communications By Investing.com - Investing.com South Africa
Turn Therapeutics Appoints Veteran Capital Markets - GlobeNewswire
Turn Therapeutics (NASDAQ: TTRX) names Andrew Scott VP of Corporate Communications; 30 years - Stock Titan
Turn Therapeutics launches webinar series for shareholder engagement - MSN
Jennifer Doudna spinoff aims to turn patients’ immune cells into CAR-T fighters with single shot - statnews.com
Turn Therapeutics Inc (TTRX) Stock News Today - TipRanks
Turn Therapeutics files to sell 7M shares off common stock for holders - MSN
TTRX News Today | Why did Turn Therapeutics stock drop today? - MarketBeat
Turn Therapeutics (TTRX) Stock Trends and Sentiment 2025 - MarketBeat
Turn Therapeutics (TTRX) Competitors and Alternatives 2025 - MarketBeat
Turn Therapeutics (TTRX) 10K Form and SEC Filings 2025 - MarketBeat
Turn Therapeutics signs license deal with surgical product supplier Medline - MSN
Turn Therapeutics partners with Medline for global supply agreement By Investing.com - Investing.com Australia
Turn Therapeutics Partners with Medline for Global Expansion - TipRanks
Turn Therapeutics (NASDAQ: TTRX) teams with Medline to commercialize PermaFusion products - Stock Titan
Turn Therapeutics (TTRX) Stock Price, News & Analysis - MarketBeat
Turn Therapeutics (NASDAQ:TTRX) Insider Purchases $65,715.60 in Stock - Defense World
Insider Stock Purchases: October 30, 2025 - Quiver Quantitative
Turn Therapeutics appoints Kester to board of directors - MSN
Form 424B5 Turn Therapeutics Inc. - StreetInsider
What is the current Price Target and Forecast for Turn Therapeutics Inc. (TTRX) - Zacks Investment Research
Should I buy Turn Therapeutics Inc. (TTRX) - Zacks Investment Research
Turn Therapeutics Inc Stock (TTRX) Financials Data
There is no financial data for Turn Therapeutics Inc (TTRX). Check out other stocks for more information.
Revenue
Net Income
Cash Flow
EPS
Turn Therapeutics Inc Stock (TTRX) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| GOLDEN ARTHUR F | Director |
Nov 24 '25 |
Buy |
3.44 |
9,868 |
33,946 |
60,602 |
| GOLDEN ARTHUR F | Director |
Nov 21 '25 |
Buy |
2.87 |
20,532 |
58,927 |
50,734 |
| Chaudhary Zuraiz | See Remarks |
Nov 20 '25 |
Buy |
2.61 |
1,450 |
3,784 |
9,000 |
| Chaudhary Zuraiz | See Remarks |
Nov 21 '25 |
Buy |
3.29 |
1,000 |
3,290 |
10,000 |
| Chaudhary Zuraiz | See Remarks |
Nov 17 '25 |
Buy |
3.62 |
2,500 |
9,050 |
7,550 |
| Chesed Abraham | Board Observer |
Oct 23 '25 |
Buy |
4.60 |
14,286 |
65,716 |
1,447,268 |
| Chaudhary Zuraiz | See Remarks |
Oct 23 '25 |
Buy |
4.95 |
5,050 |
24,998 |
5,050 |
| GOLDEN ARTHUR F | Director |
Oct 23 '25 |
Buy |
4.95 |
20,202 |
100,000 |
30,202 |
1.08%
0.91%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):